CHF42.54 close: Bristol-Myers Squibb (BMY.SW, SIX) 20 Feb 2026 oversold bounce

BMY.SW stock closed at CHF 42.54 on 20 Feb 2026, down 4.40% from the prior session. We see a classic oversold bounce setup after the drop. Trading volume spiked vs average with relVolume 22.73, signalling concentrated flows into the SIX-listed Bristol-Myers Squibb Company. The move creates a short-term trade window for traders who want a defined risk entry ahead of the company’s next earnings on 30 Apr 2026.

BMY.SW stock: Today’s move and technical setup

The most important fact is the price action. BMY.SW stock fell from the previous close CHF 44.50 to CHF 42.54, a -4.40% decline. This produced a tight single-price day low and high at CHF 42.54 and a very low reported volume of 500.00, against an average volume of 22.00. Relative volume reads 22.73, suggesting outsized order flow into a normally quiet Swiss listing.

Technically the MACD reads -0.11 with a histogram at -0.07, while ADX prints 100.00 showing strong trend momentum. ATR is 0.20, so daily moves are small in absolute terms. Traders should watch CHF 42.00 as near-term support and CHF 44.75 as the 52-week high reference.

Fundamentals and valuation

Bristol-Myers Squibb Company (BMY.SW) lists on the SIX market in Switzerland but reports US operations. Key metrics show EPS CHF 2.66 and PE 15.99. Market cap is roughly CHF 70.70 billion, and the dividend yield sits near 3.50%, with payout ratio 72.54%. These figures position BMY.SW stock cheaper on PE than the broader healthcare cohort, where the sector average PE is higher.

Balance-sheet signals matter for the trade. Debt-to-equity runs 3.45, and net-debt-to-EBITDA is near 3.00, which increases downside risk if revenue weakens. Free cash flow yields are robust, roughly 23.32%, supporting the dividend and buyback optionality.

Sector context and recent news

Healthcare peers have outperformed year-to-date, leaving BMY.SW stock relatively lagging. Sector momentum can influence any bounce attempt, especially for stocks with large US operations listed in Switzerland. We track ETF flows and dividend strategies for context, which can shift demand for global healthcare names source.

Company-specific news is light today; the next major calendar item is the earnings announcement on 30 Apr 2026. For market flow color and advisor moves affecting healthcare demand, see recent advisor and industry notes source.

Meyka AI rates BMY.SW with a score out of 100 and forecast

Meyka AI rates BMY.SW with a score of 73.32 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.

Meyka AI’s forecast model projects CHF 39.34 as a one-year model estimate. Compared with the current price CHF 42.54, the model implies a -7.53% difference. Forecasts are model-based projections and not guarantees.

Risk, upside and trading idea for an oversold bounce

This setup suits a defined-risk bounce trade. Entry can be near current levels CHF 42.54, with a tight stop under CHF 41.00 to limit downside. Conservative target CHF 46.00, base target CHF 43.50, and extended target CHF 47.00 reflect resistance and mean-reversion potential. Position sizing should assume volatility and a possible earnings gap.

Primary risks: high leverage metrics, patent competition in key franchises, and a heavier US revenue mix that can react to macro news. If earnings on 30 Apr 2026 disappoint, the bounce could fail and turn into a longer decline.

Quick technical levels and execution checklist

Short checklist for an oversold bounce attempt: confirm a close above CHF 43.00, watch intraday volume exceed 1,000.00, and use a stop-loss near CHF 41.00. Use limit entries to avoid chasing spikes. Scale out at CHF 44.50 and CHF 46.00 for disciplined exits.

We recommend traders combine technical triggers with exposure limits. For investors, wait for clearer earnings or clinical updates before adding larger positions.

Final Thoughts

BMY.SW stock closed CHF 42.54 on 20 Feb 2026 after a -4.40% fall, creating an oversold bounce opportunity for short-term traders. Fundamentals show a reasonable PE 15.99, EPS 2.66, and dividend yield 3.50%, but leverage metrics (debt-to-equity 3.45) raise caution. Meyka AI’s forecast model projects CHF 39.34, implying a -7.53% difference versus the current price. That model-based projection suggests limited structural upside but it does not negate short-term mean reversion.

Our tactical idea: a disciplined bounce trade with entry near CHF 42.50, stop near CHF 41.00, and layered targets at CHF 44.50 and CHF 46.00. Watch earnings on 30 Apr 2026 as the key catalyst. We include this analysis as part of Meyka AI’s AI-powered market analysis platform and remind readers that forecasts and grades are projections, not guarantees. Manage size and risk to account for sector moves and balance-sheet exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.